Poor
Misaligned
Patient Risk:
Medium
Summary
Strong alignment for atorvastatin (Lipitor) mechanism and muscle-symptom counseling, but most Pepcid (famotidine)-specific claims and Lipitor+Pepcid interaction claims are unsupported because no Pepcid labeling excerpts were provided in the supplied label sections.
Category Scores
Accurate Statements
Lipitor (atorvastatin) helps lower cholesterol levels by reducing the production of low-density lipoprotein (LDL) cholesterol in the liver.
12.1 Mechanism of Action (inhibits HMG-CoA reductase and reduces LDL production/LDL particle number in liver; mechanism supports LDL reduction).
It is advised to report muscle pain, weakness, or tenderness to a doctor promptly.
5.1 Skeletal Muscle; 17.1 Muscle Pain (advised to report unexplained muscle pain/tenderness/weakness promptly).
Grapefruit can increase the risk of side effects of Lipitor.
7.2 Grapefruit Juice (increases plasma concentrations of atorvastatin); 17.1 Muscle Pain (risk of myopathy increased with grapefruit juice consumption).
Increased risk of muscle damage may be greater in older adults or those with kidney disease.
8.5 Geriatric Use (age ≥65 predisposing factor for myopathy); 5.1 Skeletal Muscle (history of renal impairment risk factor for rhabdomyolysis).
Unsupported Statements
Pepcid (famotidine) is an H2 receptor antagonist that reduces stomach acid production.
No Pepcid/famotidine labeling excerpts were provided in the supplied label sections.
Combining Lipitor with Pepcid may increase the risk of muscle damage.
No label excerpts were provided describing Pepcid/famotidine as an interacting agent with Lipitor or that this combination increases myopathy risk.
Pepcid can increase the levels of atorvastatin in the blood.
No Pepcid/famotidine interaction labeling excerpts were provided. Supplied interaction excerpts concern other CYP3A4 inhibitors and grapefruit, not Pepcid.
Kidney function impairment may occur with Lipitor and Pepcid, particularly in individuals with pre-existing kidney disease.
No Pepcid-related kidney safety/excerpts were provided. While Lipitor labeling discusses acute renal failure secondary to rhabdomyolysis, the Pepcid-specific combination aspect is unsupported.
Both Lipitor and Pepcid can affect kidney function.
No Pepcid-related kidney safety excerpts were provided.
Pepcid can cause stomach upset, nausea, and diarrhea.
No Pepcid adverse reaction excerpts were provided.
Pepcid-related gastrointestinal side effects may be exacerbated by Lipitor.
No Pepcid interaction or GI-exacerbation excerpts were provided.
Monitoring kidney function and adjusting medication doses as needed is important.
Supplied label excerpts support monitoring skeletal muscle effects and provide Lipitor renal impairment dosing guidance (no adjustment needed for renal dysfunction in provided section), but do not support kidney-function monitoring and dose adjustment instructions specifically in the context of Lipitor+Pepcid.
Taking Lipitor and Pepcid at different times of the day may minimize potential interactions.
No labeling excerpts were provided for Pepcid or for guidance that separating dosing times minimizes interactions for Pepcid with atorvastatin.
Contradictions
Low
AI Statement
Avoid consuming grapefruit or grapefruit juice while taking Lipitor because it can increase the risk of side effects.
Label Reference
7.2 Grapefruit Juice; 17.1 Muscle Pain
Important Omissions
No label excerpts were provided regarding boxed warnings, contraindications, pregnancy/lactation, pediatric use, or comprehensive warnings/precautions beyond skeletal muscle and liver dysfunction. This prevents assessment of Pepcid-related safety omissions and overall regimen risk.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Many key claims involve Pepcid-specific mechanisms/interactions and combined-risk assertions that are not supported by the supplied labeling excerpts; this could lead to incorrect interaction expectations or monitoring focus.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Misaligned
Primary Issue
Pepcid (famotidine)-specific claims and Lipitor+Pepcid interaction/safety guidance are largely unsupported because no Pepcid label text was provided for verification.
Suggested Improvement
Remove or qualify Pepcid/famotidine-specific and Lipitor+Pepcid combination claims unless Pepcid FDA label excerpts are provided; retain only atorvastatin-supported claims (e.g., mechanism and statin myopathy counseling, grapefruit interaction as described).